TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25855621
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, oral)
Study: 25856269
Drug: Catheter-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed therapy (CDT) with low-dose hourly infusion of tissue plasminogen activator (tPA) or urokinase; average doses were 28.0 ± 11 mg tPA (n = 76) and 2,697,101 ± 936,287 International Units for urokinase (n = 23).
Study: 25856269
Drug: Catheter-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed therapy (CDT)
Study: 25856546
Drug: botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: botulinum toxin-A (BoNT-A) treatment
Study: 25858498
Drug: Cixutumumab 1
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab 1 mg/kg, 3 mg/kg, or 6 mg/kg intravenously on days 1/8/15 with doxorubicin 75 mg/m² as a 48 h infusion on day 1 of a 21 day cycle
Study: 25858498
Drug: Cixutumumab alone
Normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab alone after six cycles of combination therapy
Study: 25858546
Drug: Testosterone ablation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone ablation therapy
Study: 25858546
Drug: Estradiol replacement
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol replacement therapy
Study: 25860203
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy administered by a specialized pediatric transport team
Study: 25861217
Drug: Treatment selected
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment selected to target a somatic mutation in the tumor
Study: 25862507
Drug: Malaligned Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaligned Group (MG)
Study: 25862716
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LASac and Systolic Blood Pressure
Study: 25865468
Drug: Gliovac (ERC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliovac (ERC 1671) administered intradermally with human GM-CSF (Leukine(®)), preceded by low-dose cyclophosphamide regimen.
Study: 25865468
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard of care treatment).
Study: 25867467
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (44 μg subcutaneously three times weekly)
Study: 25870087
Drug: AUY922 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922 (70 mg) and erlotinib (150 mg)
Study: 25870087
Drug: AUY922 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922 and erlotinib (doses not specified for phase II)
Study: 25870329
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) - 3 doses at 1-month intervals, 1 additional dose 6 months later, followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later
Study: 25870329
Drug: 4-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose regimen of PCV13 followed by PPSV23
Study: 25872574
Drug: Coloplast Titan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloplast Titan IPP with NLMT and postoperative rehabilitation (daily inflation for 1 year)
Study: 25872574
Drug: Postoperative rehabilitation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative rehabilitation (daily inflation for 1 year)
Study: 25872787
Drug: Tafamidis 20
Normalized name: TAFAMIDIS 20MG TAB UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 20 mg daily
Study: 25874001
Drug: AZD0530 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0530 50 mg
Study: 25874001
Drug: AZD0530 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0530 100 mg
Study: 25874001
Drug: AZD0530 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0530 125 mg
Study: 25874991
Drug: TwHF extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF extract (10 mg three times daily for 12 months)
Study: 25876473
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1a intramuscular 30μg
Study: 25878729
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with fasting insulin (FINS)
Study: 25878729
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with homeostasis model assessment of β-cell insulin secretion (HOMA-β)
Study: 25879416
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (≤8 mg/24 h) as add-on to oral DA
Study: 25879807
Drug: Diuretics (particularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (particularly antialdosteronic diuretic agents)
Study: 25879867
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of MVA
Study: 25879867
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MVA (for vaccinia-experienced subjects)
Study: 25880400
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily for 12 weeks (with optional increase to 120 mg after 8 weeks)
Study: 25881847
Drug: Busulfan and
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan and fludarabine (Flu-BU) conditioning regimen after FLAG-IDA chemotherapy
Study: 25882434
Drug: Renal angina
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal angina index (RAI) and biomarkers (NGAL, KIM-1, l-FABP, IL-18)
Study: 25883641
Drug: Marine protein
Normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine protein supplement (MPS)
Study: 25883789
Drug: Oral salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salt and water
Study: 25883789
Drug: Intravenous isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous isotonic saline
Study: 25884189
Drug: H1 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 DNA vaccine (4 mg intramuscularly with Biojector, 3 doses at 4-week intervals)
Study: 25884189
Drug: H1 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 DNA vaccine
Study: 25884515
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg administrated p.o. twice daily for 28-day treatment cycles
Study: 25884515
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg administrated p.o. twice daily
Study: 25885553
Drug: 5% Imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Imiquimod (IMQ) cream, applied once a day, 5 days per week, for 8-16 weeks
Study: 25885553
Drug: 5% Imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Imiquimod (IMQ) cream for lesions >10 mm
Study: 25885553
Drug: 5% Imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Imiquimod (IMQ) cream for lesions <10 mm
Study: 25886021
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) dispersible formulation, 20 mg artemether/120 mg lumefantrine, given twice-daily for three days
Study: 25886021
Drug: Three-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day regimen of AL dispersible formulation
Study: 25886021
Drug: Dosing recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing recommendations for infants <5 kg
Study: 25886603
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.03 ml)
Study: 25886605
Drug: Panagen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panagen (5 mg, 6 tablets daily for 18 days during chemotherapy)
Study: 25886605
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 tablets daily for 18 days during chemotherapy)
Study: 25887027
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure titration from 65 mmHg to normal levels
Study: 25887336
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 150 mg dose of fluconazole
Study: 25887777
Drug: AFM13 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFM13 at doses of 0.01 to 7 mg/kg body weight
Study: 25887777
Drug: AFM13 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFM13 at doses of ≥1.5 mg/kg
Study: 25887777
Drug: AFM13 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AFM13 treatment
Study: 25888272
Drug: ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ramucirumab 8 mg/kg on days 1 and 15 and paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle
Study: 25888403
Drug: Closed-loop fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop fluid administration system
Study: 25888646
Drug: PCV13 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (3 doses) followed by PPSV23 (1 dose)
Study: 25888856
Drug: Couples' Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples' Health CoOp intervention targeting men who use alcohol and other drugs and engage in unprotected sex, and their main female sex partners. The intervention includes components addressing substance use, sex risk, HIV and other STIs, gender roles, gender-based violence, communication skills, and goal-setting activities.
Study: 25888961
Drug: Entropy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entropy in the ophthalmic artery
Study: 25889044
Drug: Pradigastat 20
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 20 mg
Study: 25889044
Drug: Pradigastat 40
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 40 mg
Study: 25889305
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (3 g/day for 6 weeks)
Study: 25890322
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with nutritional supplements
Study: 25891174
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg or 10 mg per kg every 3 weeks or 10 mg per kg every 2 weeks)
Study: 25891993
Drug: C-FLAG (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-FLAG (fludarabine and cytarabine as a 24-hr continuous infusion without idarubicin)
Study: 25892292
Drug: Serum magnesium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum magnesium (se Mg) deficiency group
Study: 25892292
Drug: Serum magnesium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum magnesium (se Mg)
Study: 25895428
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks
Study: 25895616
Drug: Cediranib 30mg
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30mg oral daily (od)
Study: 25896788
Drug: 4 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 hours SHD using a dialysate flow of 500 mL/min
Study: 25897792
Drug: Lomitapide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomitapide (5 mg to 60 mg a day, maximum)
Study: 25898341
Drug: Acceptance-based Separated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based Separated Family Treatment (ASFT)
Study: 25898693
Drug: Dermatophagoides mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatophagoides mix (300, 600, 3000, 6000, and 15000 SQ+) administered at weekly intervals with 1 maintenance injection (15000 SQ+) 2 weeks after the last updosing injection.
Study: 25899176
Drug: Budesonide/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol combination (BFC)
Study: 25899176
Drug: Fluticasone/salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol combination (FSC)
Study: 25899782
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine (escalating doses of fludarabine: 15, 45, and 75 mg/m(2))
Study: 25899782
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of adenoviral vector expressing E. coli PNP and intravenous fludarabine
Study: 25900065
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (all doses)
Study: 25900065
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab 500 mg/m²
Study: 25900182
Drug: Cixutumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (10 mg/kg i.v.), Everolimus (10 mg p.o. daily), Octreotide LAR (20 mg i.m. every 21 days)
Study: 25900467
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of sedatives and analgesics
Study: 25901095
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam given 30 min before a clamp during euglycemia
Study: 25901095
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam given 30 min before a clamp during hypoglycemia
Study: 25901095
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam during euglycemia
Study: 25901286
Drug: AGS-003 in
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS-003 in combination with sunitinib
Study: 25901550
Drug: Life-sustaining treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-sustaining treatments (mechanical ventilation, vasopressors, renal replacement therapy)
Study: 25902842
Drug: idursulfase 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: idursulfase 0.5 mg/kg weekly for one year
Study: 25903963
Drug: PEI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEI regimen (Cisplatin 20 mg/m2, Etoposide 75 mg/m2, Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks)
Study: 25904000
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (eGFR > 30 ml/min)
Study: 25904635
Drug: Variant rs705702-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variant rs705702-G near RAB5B and SUOX
Study: 25906048
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving therapy (BCT) with surgical removal of the tumor (lumpectomy) followed by radiation treatment.
Study: 25907171
Drug: Budesonide/formoterol 80/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 80/4.5 μg one inhalation b.i.d.
Study: 25907171
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 μg one inhalation b.i.d.
Study: 25907171
Drug: Budesonide/formoterol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 2 x 160/4.5 μg b.i.d.
Study: 25907621
Drug: Ipilimumab 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab 10mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Study: 25908679
Drug: Medication incidents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication incidents identified among primary care patients
Study: 25909192
Drug: 10mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg of oral zinc
Study: 25909513
Drug: Other atypical
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other atypical antipsychotics
Study: 25911223
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics for pulmonary exacerbation (PEx) treatment
Study: 25911554
Drug: Bendamustine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine plus bortezomib and prednisone (1.3 mg/m(2) bortezomib twice weekly for 6 weeks, 90 mg/m(2) bendamustine on days 1 and 4)
Study: 25912075
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIII Fc fusion protein (rFVIIIFc), starting regimen: twice-weekly prophylaxis (Day 1: 25 IU kg(-1); Day 4: 50 IU kg(-1)); adjusted dose (≤ 80 IU kg(-1)) and dosing interval (≥ 2 days) as needed.
Study: 25915616
Drug: IPTp-MQ (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTp-MQ (2 doses)
Study: 25915616
Drug: IPTp-MQ (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTp-MQ (3 doses) added to CTXp
Study: 25915780
Drug: IMMU-132 (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMU-132 (17.5 mg/kg; twice weekly × 4 weeks)
Study: 25915780
Drug: IMMU-132 (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMU-132 (dosing schemes: every other week, weekly, or twice weekly)
Study: 25916910
Drug: Postprandial lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial lipid metabolism
Study: 25917561
Drug: New-generation P2Y₁₂
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-generation P2Y₁₂ receptor antagonists
Study: 25918250
Drug: Cetuximab (400mg/m²,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400mg/m², then 250mg/m²) and trastuzumab (3.0 or 4.0mg/kg, then 1.5 or 2.0mg/kg weekly)
Study: 25918559
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of sirolimus
Study: 25918559
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of sirolimus
Study: 25921059
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg by mouth daily
Study: 25921689
Drug: TDF 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 150 mg once daily
Study: 25921689
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg every 48 hours
Study: 25921689
Drug: TDF 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 150 mg once daily and TDF 300 mg every 48 hours
Study: 25923040
Drug: Postoperative copeptin
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative copeptin levels measured daily until discharge
Study: 25923040
Drug: Copeptin <2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin <2.5 pmol/L on postoperative day 1
Study: 25923040
Drug: Copeptin >30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin >30 pmol/L on postoperative day 1
Study: 25923426
Drug: Concurrent detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent detection of pathogens
Study: 25923549
Drug: AZD9291 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 (20 to 240 mg once daily)
Study: 25923603
Drug: Essential amino-acid
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino-acid supplements
Study: 25924990
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 μg) administered after placebo; 4 weeks of treatment with salmeterol 50 μg twice daily.
Study: 25924991
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Study: 25924991
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Study: 25924991
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg and 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Study: 25925619
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin (0.1-2.4 mg/kg every 21 days) as a single agent
Study: 25925619
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin combined with rituximab (375 mg/m2)